BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 28800127)

  • 1. Mnt modulates Myc-driven lymphomagenesis.
    Campbell KJ; Vandenberg CJ; Anstee NS; Hurlin PJ; Cory S
    Cell Death Differ; 2017 Dec; 24(12):2117-2126. PubMed ID: 28800127
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mnt-deficient mammary glands exhibit impaired involution and tumors with characteristics of myc overexpression.
    Toyo-oka K; Bowen TJ; Hirotsune S; Li Z; Jain S; Ota S; Escoubet-Lozach L; Garcia-Bassets I; Lozach J; Rosenfeld MG; Glass CK; Eisenman R; Ren B; Hurlin P; Wynshaw-Boris A
    Cancer Res; 2006 Jun; 66(11):5565-73. PubMed ID: 16740691
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development and survival of MYC-driven lymphomas require the MYC antagonist MNT to curb MYC-induced apoptosis.
    Nguyen HV; Vandenberg CJ; Ng AP; Robati MR; Anstee NS; Rimes J; Hawkins ED; Cory S
    Blood; 2020 Mar; 135(13):1019-1031. PubMed ID: 31978211
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Switch from Mnt-Max to Myc-Max induces p53 and cyclin D1 expression and apoptosis during cholestasis in mouse and human hepatocytes.
    Yang H; Li TW; Ko KS; Xia M; Lu SC
    Hepatology; 2009 Mar; 49(3):860-70. PubMed ID: 19086036
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The activities of MYC, MNT and the MAX-interactome in lymphocyte proliferation and oncogenesis.
    Link JM; Hurlin PJ
    Biochim Biophys Acta; 2015 May; 1849(5):554-62. PubMed ID: 24731854
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chromatin dynamics at the hTERT promoter during transcriptional activation and repression by c-Myc and Mnt in Xenopus leavis oocytes.
    Wahlström T; Belikov S; Arsenian Henriksson M
    Exp Cell Res; 2013 Dec; 319(20):3160-9. PubMed ID: 23860446
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Of Myc and Mnt.
    Hooker CW; Hurlin PJ
    J Cell Sci; 2006 Jan; 119(Pt 2):208-16. PubMed ID: 16410546
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FoxO3 suppresses Myc-driven lymphomagenesis.
    Vandenberg CJ; Motoyama N; Cory S
    Cell Death Dis; 2016 Jan; 6(1):e2046. PubMed ID: 26764572
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mnt-Max to Myc-Max complex switching regulates cell cycle entry.
    Walker W; Zhou ZQ; Ota S; Wynshaw-Boris A; Hurlin PJ
    J Cell Biol; 2005 May; 169(3):405-13. PubMed ID: 15866886
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The MNT transcription factor autoregulates its expression and supports proliferation in MYC-associated factor X (MAX)-deficient cells.
    Lafita-Navarro MC; Liaño-Pons J; Quintanilla A; Varela I; Blanco R; Ourique F; Bretones G; Aresti J; Molina E; Carroll P; Hurlin P; Romero OA; Sanchez-Céspedes M; Eisenman RN; Delgado MD; León J
    J Biol Chem; 2020 Feb; 295(7):2001-2017. PubMed ID: 31919096
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mnt, a novel Max-interacting protein is coexpressed with Myc in proliferating cells and mediates repression at Myc binding sites.
    Hurlin PJ; Quéva C; Eisenman RN
    Genes Dev; 1997 Jan; 11(1):44-58. PubMed ID: 9000049
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MYC needs MNT.
    Link JM; Hurlin PJ
    Cell Cycle; 2013 Feb; 12(3):385-6. PubMed ID: 23324353
    [No Abstract]   [Full Text] [Related]  

  • 13. Loss of the Max-interacting protein Mnt in mice results in decreased viability, defective embryonic growth and craniofacial defects: relevance to Miller-Dieker syndrome.
    Toyo-oka K; Hirotsune S; Gambello MJ; Zhou ZQ; Olson L; Rosenfeld MG; Eisenman R; Hurlin P; Wynshaw-Boris A
    Hum Mol Genet; 2004 May; 13(10):1057-67. PubMed ID: 15028671
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inflammatory disease and lymphomagenesis caused by deletion of the Myc antagonist Mnt in T cells.
    Dezfouli S; Bakke A; Huang J; Wynshaw-Boris A; Hurlin PJ
    Mol Cell Biol; 2006 Mar; 26(6):2080-92. PubMed ID: 16507988
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mnt transcriptional repressor is functionally regulated during cell cycle progression.
    Popov N; Wahlström T; Hurlin PJ; Henriksson M
    Oncogene; 2005 Dec; 24(56):8326-37. PubMed ID: 16103876
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A critical role for Mnt in Myc-driven T-cell proliferation and oncogenesis.
    Link JM; Ota S; Zhou ZQ; Daniel CJ; Sears RC; Hurlin PJ
    Proc Natl Acad Sci U S A; 2012 Nov; 109(48):19685-90. PubMed ID: 23150551
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MicroRNA miR-210 modulates cellular response to hypoxia through the MYC antagonist MNT.
    Zhang Z; Sun H; Dai H; Walsh RM; Imakura M; Schelter J; Burchard J; Dai X; Chang AN; Diaz RL; Marszalek JR; Bartz SR; Carleton M; Cleary MA; Linsley PS; Grandori C
    Cell Cycle; 2009 Sep; 8(17):2756-68. PubMed ID: 19652553
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mnt: a novel Max-interacting protein and Myc antagonist.
    Hurlin PJ; Qúeva C; Eisenman RN
    Curr Top Microbiol Immunol; 1997; 224():115-21. PubMed ID: 9308234
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mnt loss triggers Myc transcription targets, proliferation, apoptosis, and transformation.
    Nilsson JA; Maclean KH; Keller UB; Pendeville H; Baudino TA; Cleveland JL
    Mol Cell Biol; 2004 Feb; 24(4):1560-9. PubMed ID: 14749372
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Functional interactions among members of the MAX and MLX transcriptional network during oncogenesis.
    Diolaiti D; McFerrin L; Carroll PA; Eisenman RN
    Biochim Biophys Acta; 2015 May; 1849(5):484-500. PubMed ID: 24857747
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.